Unity Biotechnology Inc (fra:9U90) Share Price

Company Profile

Business description
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
Contact
285 East Grand Avenue
South San FranciscoCA94080
USA
T: +1 650 416-1192
E: [email protected]
https://www.unitybiotechnology.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees

Recommended

This share is trading at the lowest price to fair value of the 14 companies on the list.

Angus Hewitt, CFA | 05 January 2026

Despite a surging share price a weakening competitive position causes a reassessment of our view.

Shane Ponraj, CFA | 05 January 2026

We believe these companies’ strong ESG management practices give them a long-term advantage.

Margaret Giles | 04 January 2026

Index	Last price	Change	% Change
All Ordinaries	8,996.90	37.80	-0.42%
CAC 40	8,247.33	35.83	0.44%
DAX 40	24,896.94	28.25	0.11%
Dow JONES (US)	49,198.70	221.52	0.45%
FTSE 100	10,132.02	127.45	1.27%
HKSE	26,710.45	363.21	1.38%
NASDAQ	23,435.53	39.70	0.17%
Nikkei 225	52,518.08	685.28	1.32%
NZX 50 Index	13,663.58	76.35	0.56%
S&P 500	6,918.15	16.10	0.23%
S&P/ASX 200	8,682.80	45.80	-0.52%
SSE Composite Index	4,083.67	60.25	1.50%